A novel ERK1/2 inhibitor has potent activity in KRAS-mutant non-small cell lung cancer models

被引：0
|
作者：
Courtin, Aurelie [1 ]
Bevan, Luke [1 ]
Heightman, Tom [1 ]
Kidane, Birikiti [1 ]
Kucia-Tran, Justyna [1 ]
Lyons, John [1 ]
Muench, Sandra [1 ]
Shah, Alpesh [1 ]
Stanczuk, Lukas [1 ]
Thompson, Neil [1 ]
Wallis, Nicola [1 ]
Wilsher, Nicola [1 ]
Munck, Joanne [1 ]
机构：
[1] Astex Pharmaceut, Cambridge, England
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-5781
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5781
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells
    Xie, Chun
    Li, Ying
    Li, Lan-Lan
    Fan, Xing-Xing
    Wang, Yu-Wei
    Wei, Chun-Li
    Liu, Liang
    Leung, Elaine Lai-Han
    Yao, Xiao-Jun
    [J]. FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [32] The Path to Personalized Treatment in KRAS-Mutant Non-Small Cell Lung Cancer: A Review of Targeted Therapies and Immunotherapy
    Shu, Chun-Lu
    Liu, Yu -Ling
    [J]. CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 3485 - 3492
  • [33] An inhibitor to the WEE1 kinase has pre-clinical activity in mutant KRAS/LKB1-deficient non-small cell lung cancer
    Richer, Amanda L.
    Cala, Jacqueline M.
    O'Brien, Kelley
    Carson, Vashti M.
    Whitsett, Timothy G.
    Inge, Landon J.
    [J]. CANCER RESEARCH, 2016, 76
  • [34] Clinical characteristics and outcomes of Chinese patients with KRAS-mutant non-small cell lung cancer after chemotherapy
    Zheng, Yawen
    Lai, Qinghua
    Zhao, Hanxi
    Li, Xiaolin
    Sun, Xiaorong
    Xing, Ligang
    [J]. CANCER COMMUNICATIONS, 2021, 41 (11) : 1234 - 1238
  • [35] Anti-tumor activity of a TBK1/IKBKE inhibitor in combination with a MEK inhibitor in KRAS mutant colorectal and non-small cell lung cancer models
    Stinson, S.
    He, J.
    Hollenback, D.
    Jia, J.
    Kaplan, J.
    Venkataramani, C.
    Babusis, D.
    Guevara, F.
    Nelson, T.
    Cavanaugh, J.
    Asahina, H.
    Ray, A.
    Sicinska, E.
    Fuchs, C.
    Barbie, D.
    Wong, K. K.
    Ng, K.
    Dornan, D.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 69 : S146 - S146
  • [36] Cyclin D1 expression as a potential prognostic factor in advanced KRAS-mutant non-small cell lung cancer
    Luangdilok, Sutima
    Wanchaijiraboon, Passakorn
    Chantranuwatana, Poonchavist
    Teerapakpinyo, Chinachote
    Shuangshoti, Shanop
    Sriuranpong, Virote
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (06) : 959 - 966
  • [37] Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden
    Ramin Salehi-Rad
    Rui Li
    Linh M. Tran
    Raymond J. Lim
    Jensen Abascal
    Milica Momcilovic
    Stacy J. Park
    Stephanie L. Ong
    Maryam Shabihkhani
    Zi Ling Huang
    Manash Paul
    David B. Shackelford
    Kostyantyn Krysan
    Bin Liu
    Steven M. Dubinett
    [J]. Cancer Immunology, Immunotherapy, 2021, 70 : 2389 - 2400
  • [38] Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden
    Salehi-Rad, Ramin
    Li, Rui
    Tran, Linh M.
    Lim, Raymond J.
    Abascal, Jensen
    Momcilovic, Milica
    Park, Stacy J.
    Ong, Stephanie L.
    Shabihkhani, Maryam
    Huang, Zi Ling
    Paul, Manash
    Shackelford, David B.
    Krysan, Kostyantyn
    Liu, Bin
    Dubinett, Steven M.
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (08) : 2389 - 2400
  • [39] ERK5 suppression overcomes FAK inhibitor resistance in mutant KRAS-driven non-small cell lung cancer
    Pozzato, Chiara
    Outeiro-Pinho, Goncalo
    Galie, Mirco
    Ramadori, Giorgio
    Konstantinidou, Georgia
    [J]. EMBO MOLECULAR MEDICINE, 2024,
  • [40] The role of EphA2 in KRAS mutant non-small cell lung cancer
    Amato, Katherine
    Wang, Shan
    Hastings, Andrew
    Chen, Haiying
    Colvin, Daniel
    Ye, Fei
    Chen, Jin
    [J]. MOLECULAR CANCER RESEARCH, 2014, 12
12345